



FIG. 1

1/17



2/17

Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146



3/17

CVT-3146 and Coronary Flow Velocity *Duration of Effect:*

Duration ≥ 2.5 Baseline	
Dose (n)	Mean $\pm$ SEM
10 μg (4)	0
30 μg (4)	0
100 μg (3)	0.2 $\pm$ 0.2 minutes
300 μg (4)	2.2 $\pm$ 1.3 minutes
400 μg (8)	2.8 $\pm$ 0.8 minutes
500 μg (4)	2.9 $\pm$ 1.3 minutes

Figure 3

4/17

Time Course of APV Ratio (CVT-3146 400 µg)





Figure 4

5/17



6/17

Time Course of Blood Pressure (CVT-3146 400 µg)




Figure 6

7/17


All Drug-Related Adverse Events Were Mild and Transient

Adverse Event	All Doses	
	(n = 36)	400 µg (n = 9)
chest discomfort	3	3
increased heart rate	3	1
hypotension	2	2
flushing	2	1
shortness of breath	2	0
funny taste in mouth	1	0
sensation in mouth, sinus, and chest	1	0
headache	1	0
tingling in hands	1	1
heart racing	1	1
bradycardia	1	1
lightheadedness	1	1
cough	1	0
nausea and vomiting	1	0

Figure 7


8/17

Figure 8




9/17

Figure 9




10/17

Figure 10




11/17

Figure 11




12/17

Figure 12




13/17

Figure 13




14/17

Figure 14



15/17

Figure 15



16/17




Figure 16




Figure 17

17/17




Figure 18